THE ARVs2 in the Malaysian MOH Drug

THE ARVs2 in the Malaysian MOH Drug List and their patent status are as
follows:
1. Nucleoside reverse transcriptase inhibitors (NRTI)
Stavudine (not patented)
Didanosine (patented)
Zidovudine + Lamivudine combination (patented)
2. Protease Inhibitors
Ritonavir (not patented)
Indinavir (patented)
3. Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Efavirenz (patented)
Nevirapine (not patented)
Malaysia’s practice in providing access to ARVs at that time was as follows:
1. Monotherapy was free in MOH hospitals.

Results (Indonesian) 2:

THE ARVs2 di Malaysia Depkes Daftar Obat dan status paten mereka adalah sebagai
berikut:
1. Nucleoside reverse transcriptase inhibitor (NRTI)
Stavudine (tidak dipatenkan)
ddI (dipatenkan)
kombinasi Lamivudine (dipatenkan) AZT +
2. Protease Inhibitor
Ritonavir (tidak dipatenkan)
Indinavir (dipatenkan)
3. Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Efavirenz (dipatenkan)
Nevirapine (tidak dipatenkan)
praktek Malaysia dalam menyediakan akses ARV pada saat itu adalah sebagai berikut:
1. Monoterapi gratis di rumah sakit Depkes.